The FDA approved a blood-based companion diagnostic for osimertinib for use in certain patients with non–small cell lung cancer, according to the drug’s manufacturer. Approximately two-thirds of ...

Foundation Medicine received a new companion diagnostic approval from the FDA for its FoundationOne CDx test—the product’s 19th indication, now for selecting breast cancer patients for treatment with ...

Qiagen announced that it has received marketing approval from the Food and Drug Administration (FDA) for its therascreen EFGR RGQ PCR Kit as a companion diagnostic to Iressa (geftinib; AstraZeneca) ...

Myriad Genetics, Inc. MYGN received the FDA clearance for its BRACAnalysis CDx, which is to be used as a companion diagnostic test by care providers to identify patients with metastatic pancreatic ...

Assay will predict which patients are best suited to the therapeutic that targets the steroid sulfatase enzyme. bioMérieux agreed to develop a companion test for Ipsen’s Phase I breast cancer drug ...

(RTTNews) - Biocartis Group NV, a Belgium-based molecular diagnostics company, announced Wednesday that it has entered into an agreement with British drug major AstraZeneca Plc. (AZN, AZN.L) for the ...

The universe of precision medicine in oncology is large and expanding. With new targeted drugs and companion testing, people with mutation-driven cancers now have care opportunities that have never ...

Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. Maybe it takes a certain set of experiences like going to medical school and ...

Self-tests for COVID-19, also referred to as home or over-the-counter (OTC) tests, are becoming widely available in the U.S. and throughout the world. Self-tests allow people to test frequently and ...

GERMANTOWN, Md. & HILDEN, Germany & SAN DIEGO--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based ...